LL-1c

General Information


DRACP ID  DRACP02381

Peptide Name   LL-1c

Sequence  FLGALWHALSHLL

Sequence Length  13

UniProt ID  P80399 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
PANC-1 Pancreatic ductal adenocarcinoma Carcinoma IC50>120 μM MTT assay 2 h 1
A549 Lung adenocarcinoma Carcinoma IC50=59 μM MTT assay 2 h 1

Hemolytic Activity  Human erythrocytes: 0% Hemolysis=30 µM

Normal (non-cancerous) Cytotoxicity  MCF-10A: IC50>120 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02381

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C73H108N18O15

Absent amino acids  CDEIKMNPQRTVY

Common amino acids  L

Mass  169202

Pl  7.72

Basic residues  2

Acidic residues  0

Hydrophobic residues  9

Net charge  2

Boman Index  2175

Hydrophobicity  130

Aliphatic Index  165.38

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  5500

Absorbance 280nm  458.33

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22526264

Title  Activity and selectivity of histidine-containing lytic peptides to antibiotic-resistant bacteria

Doi 10.1007/s00203-012-0810-5

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_13995

DRACP is developed by Dr.Zheng's team.